EndoCellutions, Inc. is a Massachusetts-based medical device company developing technologies to improve the sourcing, concentrating, and delivering of stem cells to enable regenerative medicine. Patients and physicians are encouraged by the number of authoritative studies demonstrating that concentrated stem cells harvested from bone marrow aspirate, adipose tissue, cord blood and afterbirth tissue such as Wharton’s jelly can reverse disease processes and facilitate repair of damaged tissue. For example, stem cells from these tissues are being studied in orthopedics, heart disease, cancer, diabetes, and vascular disease (information from www.clinicaltrials.gov). This research supports the transition from invasive treatments and surgical interventions to the use of non-invasively harvested and concentrated stem cells. This revolution will result in more efficacious, safer treatment of serious conditions, at significantly less cost.